GRI Bio, Inc. has announced expected interim and topline data readouts from its Phase 2a biomarker study for the lead program GRI-0621, aimed at treating idiopathic pulmonary fibrosis (IPF), in Q2 and ...

Variant Bio, a private biotech firm, said on Tuesday it has launched a platform that uses artificial intelligence on genetic ...

Synthetic fertilizer has, until now, been the primary way for farmers to feed the world but is one of agriculture’s leading contributors to global greenhouse gas emissions and is a significant driver ...

Cabaletta Bio focuses on autoimmune diseases with a potential best-in-class cell therapy, CABA-201, showing promise in early studies. Its stock price rose >$25 due to positive data produced by a drug ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today ...

Vor Bio announces a $55.6 million PIPE to fund clinical trials and expects to report updated data in 2025. Vor Bio, a clinical-stage cell and genome engineering company, announced a securities ...

Company preparing to initiate first-in-human Phase 1 study of CRMA-1001 in early 2026 nChroma Bio, a genetic medicines company advancing in vivo delivery of innovative cargoes to overcome the ...

WALTHAM, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe ...

For many years, the landscape of data center innovation has been dominated by solid-state electronics. The relentless pursuit of faster chips, denser racks and larger facilities has been the mantra ...